← All trials
NCT04423341
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Feb 28, 2021
- First posted
- Jun 9, 2020
- Last posted
- Jun 9, 2020
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Silkiss Eye SurgeryLead sponsor
- GW Pharmaceuticals Ltd.Collaborator
- Benign Essential Blepharospasm Research FoundationCollaborator
- Silkiss Eye SurgeryReponsible party - principal investigator
- Smith-Kettlewell Eye Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.